Las farmacéuticas se interesan por la Crispr, técnica genética que revolucionará la medicina

Una de las últimas técnicas que se han desarrollado en el área de la biotecnología y que puede ser revolucionaria para el campo de la medicina es la Crispr. Actualmente, empresas farmaceúticos como la AstraZeneca empiezan a hacer inversiones en torno a ella.

Crispr, iniciales en ingles de  “Repeticiones Palindrómicas Cortas Espaciadas entre sí y Agrupadas». Nos permite modificar la disposición de cualquiera de los 23 pares de cromosomas de forma más rápida, eficaz y detallada. Sin equivocaciones, ni mutaciones en el organismo.

Su uso para la medicina puede ser un gran avance ya que abre la puerta la posibilidad de detectar cuál es el problema en la secuencia en el ADN y sustituirla por el orden correcto. De esta forma las farmacéuticas podrán eliminar el gen detonante de la enfermedad y emplearlo para probar fármacos para su tratamiento.

Más info:  http://ow.ly/IRGXT

Fuente: Enpositivo.com 

Download Press

Related Posts

Menu
Sensor pH 1

Publications numbers

CA2938155 (A1)

CN106104265 (A)

EP3106865 (A1)

IN201617025892 (A)(A2)

JP2017505443 (A)

KR20160119096 (A)

MX2016010017 (A)

WO2015121516 (A1)

US10067085 (B2)

US2016021926 (A)

×
Sensor pH 2

Publications numbers

ES2597129 (B1)

WO2017009510 (A1)

CN107850565 (A)

EP3324177 (A1)

IN201717045992 (A)

JP2018520355 (A)

KR20180029044 (A)

WO2017009510 (A1)

US10254243 (B2)

×
Lector pH

Publications numbers

EP2515104 (A2)

ES1071520 (U)

WO2011073484 (A2)

US2016061813 (A1)

×
Lit Control - pH Up

Publications numbers

EP3130337 (B1)

ES2486442 (B1)

WO2015150609 (A1)

×
Lit Control - pH Up

Publications numbers

CA2950036 (A1)

CN106456646 (A)

EP3150208 (A1)

ES2552706 (A1)

IN201617039469 (A)

JP2017516791 (A)

KR20170005020 (A)

MX2016015577 (A1)

WO2015181412 (A1)

US10149851 (B2)

×
Lit Control - pH Down

Publications numbers

CN106232143 (A)

EP3130352 (A1)

ES2486441 (A1)

IN201617031655 (A)

KR20160133002 (A)

MX2016012302 (A)

WO2015150608 (A1)

US20170106032 (A1)

US2019216873 (A1)

×
Lit Control - pH Balance

Publications numbers

CN106535906 (A)

EP3162376 (A1)

ES2555166 (A1)

IN201617042534 (A)

KR20170015360 (A)

MX2016016995 (A)

WO2015197892 (A1)

US20170128469 (A1)

×
Sensor pH 1-OLD

Países

Publications numbers

Canadá

CA2938155 (A1)

China

CN106104265 (A)

Europa

EP3106865 (A1)

España

ES2542927 (A2)

Índia

NP

Japón

JP2017505443 (A)

Corea del Sur

KR20160119096 (A)

Méjico

MX2016010017 (A)

Internacional

WO2015121516 (A1)

Estados Unidos

US2017010237 (A1)

×
Sensor pH 2

Países

Publications numbers

España

ES2597129 (A1)

Internacional

WO2017009510 (A1)

×
Sensor pH 1

Países

Publications numbers

Europa

EP2515104 (A2), (A4)

España

ES1071520 (U), (Y)

Internacional

WO2011073484 (A2), (A3)

Estados Unidos

US2013032494 (A1)

Estados Unidos

US2016061813 (A1)

×
Lit Control - pH Up

Países

Publications numbers

Europa

EP3130337 (A1)

España

ES2486442 (A1)

Internacional

WO2015/150609 (A1)

×
Lit Control - pH Up

Países

Publications numbers

Canadá

CA2950036 (A1)

China

CN106456646 (A)

Europa

EP3150208 (A1)

España

ES2552706 (A1)

Índia

NP

Japón

JP2017516791 (A)

Corea del Sur

KR20170005020 (A)

Méjico

NP

Internacional

WO2015/181412 (A1)

Estados Unidos

US2017143724 (A1)

×
Lit Control - pH Down

Países

Publications numbers

China

CN106232143 (A)

Europa

EP3130352 (A1)

España

ES2486441 (A1)

Índia

NP

Corea del Sur

KR20160133002 (A)

Méjico

MX2016012302 (A)

Internacional

WO2015/150608 (A1)

Estados Unidos

US2017/0106032 (A1)

×
Lit Control - pH Balance

Países

Publications numbers

China

CN106535906 (A)

Europa

EP3162376 (A1)

España

ES2555166 (A1)

Índia

NP

Corea del Sur

KR20170015360 (A)

Méjico

MX2016016995 (A)

Internacional

WO2015/197892 (A1)

Estados Unidos

US2017/0128469 (A1)

×
Rosendo Garganta - CEO

Board Member and Private Investor in different biotech start-ups.
Former President of Medical Devices Committee at Catalonia Association of Biotech Companies.
Master in Business Administration.
Master in International Business.
Master in Entrepreneurship & Innovation.
BSc. Industrial Engineering.
BSc. Electronic Engineering.
+10 years of experience in Business Development in MD companies.

×
Marta Aznar - QARA Director

Marta Aznar - QARA Director

QMS Manager at Mesoestetic.
Deputy Quality Manager at SANJO.
PDD at IESE.
Master in Business Administration.
BSc in Chemical Engineering.
+15 years of experience managing QA and QC in different industrial companies (pharma and automotive sectors)

×
Xavi Peris - Marketing & Sales Director

Xavi Peris - Marketing & Sales Director

Marketing Director at Rubió.
Marketing Director at Lacer.
Master in Business Administration.
BSc in Law.
+25 years in strategic marketing positions managing budgets +€20 M, sales force +300 representatives, and having launched +10 products to the market in Urology and Cardiology.

×
David Pascual - Operations Director

David Pascual - Operations Director

+15 Years of experience in strategic positions regarding prototype and production in prestigious companies as Sanyo or Ateknea.
Master’s in production management.
BSc Electronic Engineering.

×
Jordi Cuñe - Medical Director

Jordi Cuñe - Medical Director

Scientific Director at AB-Biotics
PhD in Microbiology
BSc in Food Science and Technology
BSc in Biology
+15 years of experience in strategic research positions managing the development of innovative nutraceuticals and monitoring clinical trials

×
Francisco Cabezas - Financial Director

Francisco Cabezas - Financial Director

Financial Director at Medichem.
Financial Director at Combino.
Master in Financial Management.
BSc in Business Administration.
+20 years of experience in strategic financial positions managing budgets of +€80 M, investments of +€50 M and being in charge of the M&A of Combino by Medichem Group.

×
Javier Haro - R&D Director

Javier Haro - R&D Director

System Manager at Ficosa.
R&D Manager at FTE Maximal.
R&D Manager at SANYO.
Master in Project Management.
BSc in Telecom. Engineering.
+20 years of experience in strategic R&D positions managing the development of successful products and creating R&D teams from scratch to +120 people.

×